SPDR Eafe Strategic

AstraZeneca Obesity Oral Drug Shows 10.5% Weight Loss in Trials

AstraZeneca May Suspend New Drug Supply to Europe

Bernstein Reaffirms Outperform Rating on AstraZeneca, Highlights Non-Oncology Growth Potential for 2035 Sales

SJTU Team Publishes DURABLE Study: Durvalumab Plus Anlotinib Improves Survival in Small Cell Lung Cancer

Roche rapidly develops a PCR test for Ebola within six days

AstraZeneca Reports Positive SERENA-6 Trial Results, Yet Stock Falls

Genentech to Present Clinical Data for Obesity Drugs Enicepatide and Petrelintide at ADA 2026, Roche Shares Rise 1.82%

AstraZeneca Reports EMERALD-3 Trial Results: Combination Therapy Reduces Death Risk in Liver Cancer Patients by 30%

AstraZeneca Receives FDA Approval for Imfinzi in Combination with BCG to Treat High-Risk Non-Muscle Invasive Bladder Cancer

Deutsche Bank Analyst Emmanuel Papadakis Maintains Sell Rating on AstraZeneca with £115 Target Price

Wuxi Party Secretary Meets AstraZeneca Executives to Promote Deepening Cooperation

FDA Notifies AstraZeneca to Extend PDUFA Date for Camizestrant Combination Therapy

AstraZeneca's ENHERTU Recommended in EU for HER2-Positive Solid Tumors

AstraZeneca's camizestrant combo receives positive CHMP opinion for late-stage breast cancer

AstraZeneca CEO: May Invest Over $12 Billion in Japan

AstraZeneca and Daiichi Sankyo's Datroway Approved by FDA for First-Line Treatment of TNBC

AstraZeneca's camizestrant receives positive CHMP opinion for first-line breast cancer treatment

AstraZeneca to Present Phase III Clinical Data for Liver and Breast Cancer at 2026 ASCO Meeting

French Anti-Fraud Officials Raid Nestle's Perrier Plant Amid Fraud Probe

CCSC Tech

Youlife

Core AI

Regentis Biomaterials

Epsium Enterprise

Autozi Internet Tech Global

Leslies

Mega Matrix

eLong Power

Smart Logistics Global

QEFA

EASG

EFAA

<p>VanEck has launched the MSCI EAFE Analyst Sentiment ETF (NASDAQ:VEFA), targeting outperforming international stocks as global markets recover. The ETF aims to provide exposure to developed markets, focusing on companies with improving analyst outlooks. It tracks the MSCI EAFE Analyst Sentiment Select Index, selecting 100 stocks based on various financial metrics. The fund is designed to capitalize on the narrowing performance gap between U.S. and international equities, with a quarterly rebalancing schedule.</p>

benzinga_article

Xtrackers MSCI Eafe Esg Leaders Equity

iShares MSCI EAFE

Invesco MSCI EAFE Income Advantage ETF

VanEck Capitalizes On Comeback Of International Stocks With VEFA ETF

IEFA

<p>The iShares Core MSCI EAFE ETF (IEFA) has seen a significant inflow of approximately $543 million, marking a 0.3% increase in outstanding units week-over-week. The ETF's current share price is $91.95, with a 52-week range of $66.95 to $98.83. This inflow indicates a demand for new units, which may impact the underlying holdings of the ETF. Monitoring such changes in shares outstanding is crucial for understanding ETF market dynamics.</p>

nasdaq

iShares Core MSCI EAFE

IEFA: Large Inflows Detected at ETF

SPDR Eafe Strategic(QEFA.US)

VanEck Capitalizes On Comeback Of International Stocks With VEFA ETF

IEFA: Large Inflows Detected at ETF